(Bloomberg) Billionaire investor Bill Ackman’s audacious partnership with Valeant Pharmaceuticals International Inc. to make a hostile bid for drug company Allergan Inc. in 2014 brought him a windfall of more than $2 billion even though it failed. It also led to a lawsuit by Allergan shareholders accusing Ackman of illegal insider trading. In a last-ditch bid to avoid a trial, Ackman plans to argue to a federal judge on Dec. 8 that no rules were broken and the suit should be tossed.
How Ackman Hopes to Beat Insider-Trading Lawsuit
This entry was posted in Syndicated. Bookmark the permalink.
